Volume 23, Number 10—October 2017
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
|Pt no.||Last TB drug regimen administered||Sputum smear/culture conversion, d (treatment outcome)||Dlm/Bdq exposure, d||QT before treatment, ms||QT average, ms (±SD)||QT max, ms (wk)|
|1||Cm, Mfx, Eto, Cs, PAS, Cfz, Mpm, Lfx, Amx/Clv, Lzd, Bdq, Dlm||NA/NA (failure; 4 mo after completing Bdq + Dlm treatment course, patient died because of respiratory insufficiency)||168/168||410||426 (±17.6)||450 (9)|
|2||Hd H, Cfz, Cs, E, Lzd, Dlm, Bdq; as of April 28, 2017, receving: Hd H, Cs, Cfz, cotrimoxazole||60/60 (continued treatment)||168/168||400||406 (±33.6)||462 (24)|
|3||Cm, Mfx, Bdq, Dlm, Lzd, Imp, Amx/Clv||435/104 (cured)||180/180||340||363 (±25.8)||400 (35 and 51)|
|4||Bdq, Dlm, Lzd, Cfz||30/30 (continued treatment)||155/155||394||462 (±39.8)||509 (5 and 9)|
|5||Dlm, Bdq, Cfz, Trd, Mpm, Amx/Clv||18/28 (continued treatment)||427/427||449||504 (±6.3)||520 (16)†|
*Amk, amikacin; Amx/Clv, amoxicillin/clavulanate; Bdq, bedaquiline; Cfz, clofazimine; Cm, capreomycin; Cs, cycloserine; Dlm, delamanid; E, ethambutol; Eto, ethionamide; H, isoniazid; Hd, high dose; Imp, imipenem; Lfx, levofloxacin; Lzd, linezolid; max, maximum; Mfx, moxifloxacin; Mpm, meropenem; NA, not achieved; PAS, para-aminosalicylic acid; Pto, prothionamide; Pt, patient; QT, measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle; SD, standard deviation; TB, tuberculosis; Trd, terizidone.
†At different time points, intermittent episodes of asymptomatic QTc prolongation occurred.
1These authors contributed equally to this article.
- Page created: September 18, 2017
- Page last updated: September 18, 2017
- Page last reviewed: September 18, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)